Survey
Two Week Delay: Survey on ATTR-CM and BBIO-ALNY-PFE Market Dynamic February 2025
Ticker(s): ALNY, BBIO, PFEThe survey results include 10 Cardiologists that manage 20 or more patients with ATTR-CM
How many ATTR-CM patients do you treat?
How would you best describe your practice?
- Academic:
- Community:
- Other:
What percentage (%) of your patients have a mixed ATTR-CM-ATTR-PN phenotype?
There are currently two approved treatment options –Vyndaqel/ Vyndamax (Tafamidis) from Pfizer and Attruby (Acoramidis) from BridgeBio, while Alnylam’s Amvuttra (Vutrisiran) has a PDUFA date scheduled for March 23rd. Assuming Amvuttra (Vutrisiran) is approved for ATTR-CM and is commercially available by the start of Q2, what treatment(s) do you anticipate prescribing to your treatment naïve patients in 2025?
- 1st Line
- Vyndaqel/ Vyndamax (Tafamidis) Attruby (Acoramidis) Amvuttra (Vutrisiran)
- 2nd Line
- Vyndaqel/ Vyndamax (Tafamidis)Attruby (Acoramidis)Amvuttra (Vutrisiran)
What are the most important factors in your decision-making for 1st line treatment selection? Please be specific.
How would you define 'progression on Tafamidis' in your clinical practice? Please be specific.
What key factors will determine which treatment becomes the dominant option in the 2nd-line market for patients switching from Vyndaqel/Vyndamax (Tafamidis)? Please be specific.
Do you expect Amvuttra (Vutrisiran) as an alternative modality to be the preferred option for patients switching from Vyndaqel/ Vyndamax (Tafamidis)? Select one.
- Yes
- No
- Not Sure
How important is the 'near complete stabilizer' statement on the Attruby (Acoramidis) label in your treatment decision-making? Select one.
- Not at all important
- Slightly important
- Moderately important
- Very important
- Extremely important
Do you expect Alnylam's Amvuttra (Vutrisiran) to get the same label regarding mortality and hospitalization as Vyndaqel/Vyndamax (Tafamidis) and Attruby (Acoramidis)? Please see labels below for reference:
- Yes
- No
- Not Sure
Do you expect the combination data of Alnylam's Amvuttra (Vutrisiran) and Vyndaqel/Vyndamax (Tafamidis) to be included on the label for Vutrisiran (Amvuttra) upon approval?
- Yes
- No
- Not Sure
Regarding Amvuttra (Vutrisiran), what specific label language would make it a preferred 1st-line treatment option? Please be specific.
Do you expect that coverage under Medicare Part B or Part D will make a difference for patients' preference and adoption of Amvuttra (Vutrisiran) versus Attruby (Acoramidis)? Please explain.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
